Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators, a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce it received clearance (No Objection Letter) from Health Canada to proceed with a randomized placebo-controlled clinical trial of QBKPN, a first-in-class innate immune modulator that enhances lung immunity, in the elderly (Immunosenescence [IS]-01 trial)...READ MORE

Researchers at the Vancouver Prostate Centre and BC Cancer have developed a new blood test that provides unprecedented insight into a patient’s cancer make-up, potentially allowing doctors to better select treatment options that will improve patient outcomes. The technology was outlined in a study published in Nature...READ MORE

Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries has appointed veteran strategy and M&A executive, Kitty Sahin, to the newly created role of EVP, Strategy and Corporate Development, effective immediately. In this role, Ms. Sahin will report to President and CEO Michael Stubblefield...READ MORE

Izotropic Corporation, a MedTech company commercializing IzoView, an advanced breast CT (computed tomography) imaging platform for the more accurate detection and diagnosis of breast cancer, announced it has engaged a world-leading clinical research organization ICON plc to help prepare for its upcoming clinical study and submission for market authorization in the U.S....READ MORE

Global medical device giant Medtronic plc announced it has entered into a strategic partnership agreement with Israeli diagnostics company CathWorks. Kfar Saba-based CathWorks has developed a non-invasive diagnostic systems, which is an alternative to catheters, and could to transform how coronary artery disease is diagnosed and treated...READ MORE

Roche announced that the U.S. Food and Drug Administration has granted Breakthrough Device Designation to the Elecsys® Amyloid Plasma Panel, an innovative new solution to enable Alzheimer’s disease to be detected earlier. The Elecsys Amyloid Plasma Panel test detects and measures Alzheimer’s disease biomarkers in blood plasma to indicate the need for further confirmatory testing for Alzheimer’s disease...READ MORE

AbbVie announced it has submitted a marketing authorization application to the European Medicines Agency for atogepant for the prophylaxis of migraine in adult patients who have at least four migraine days per month. The application is supported by the pivotal Phase 3 ADVANCE and PROGRESS studies evaluating the safety, efficacy, and tolerability of atogepant in adult patients with episodic migraine and chronic migraine...READ MORE

Algernon Pharmaceuticals Inc., a clinical stage Canadian pharmaceutical development company, is pleased to announce positive topline data showing that it has met the co-primary endpoint in its Phase 2 proof of concept study evaluating NP-120 (“Ifenprodil”) for the potential treatment of idiopathic pulmonary fibrosis and chronic cough...READ MORE

BioTalent Canada launched the I.D.E.A.L Biosciences Employer recognition program. This new employer recognition program, which represents Inclusivity, Diversity, Equity, and Accessibility Leadership, will recognize organizations in Canada’s bio-economy leading the way in embodying the diverse and inclusive corporate principles needed to promote growth and success in the sector...READ MORE

Roche announced the launch of the Elecsys® HCV Duo immunoassay in countries that accept the CE Mark. Elecsys HCV Duo is the first available immunoassay that allows the simultaneous and independent determination of the hepatitis C virus antigen and antibody status from a single human plasma or serum sample. This means that the test can be used to detect the early stage of infection, as well as when the patient is recovering from the virus, or showing signs of a chronic infection that may lead to other diseases, such as liver cancer...READ MORE

InMed Pharmaceuticals Inc., a leader in the research, development, manufacturing and commercialization of rare cannabinoids, announced Michael Woudenberg has been appointed Chief Operating Officer of the Company, overseeing all day-to-day operations. Mr. Woudenberg was previously Senior Vice President of Chemistry, Manufacturing and Controls...READ MORE

GSK announced an agreement with the Government of Canada for pandemic and seasonal influenza vaccines to help protect Canadian adults and children. The four-year agreement, spanning through March 2026, includes the supply of as many as 80 million doses of Arepanrix (adjuvanted pandemic influenza vaccine) in the event of an influenza pandemic(s) and a minimum of 4 million doses per year of Flulaval Tetra (seasonal influenza vaccine)...READ MORE

Providence Health Care in British Columbia has signed a multi-year agreement with Thrive Health to provide technology for all clinical areas within Providence and for all Providence sites, including St. Paul’s Hospital, Mount Saint Joseph’s Hospital, and Holy Family Hospital. “Our partnership with Thrive Health is an important part of our digital strategy for the years ahead,", said Brian Simmers (pictured), chief financial officer and vice president, people and health informatics at Providence...READ MORE

On June 29, 2022, the Québec government published a draft regulation on the process for reporting privacy breaches under the new privacy law. This regulation describes what information needs to be sent to the Commission d’accès à l’information (the CAI) and to affected individuals when a breach meets the threshold for mandatory reporting, as well as the minimum retention period for records of all confidentiality incidents...READ MORE

The life sciences industry in Québec: 1) Nearly 715 companies employing over 36,930 people and supporting almost as many jobs in public research centres and various related service companies. 2) Nearly 30,000 students enrolled in life sciences programs in colleges and universities, producing 7,600 graduates per year. 3) Shipments totalling $5.7 billion in 2020, which make up 3.7% of all manufacturing shipments...READ MORE

BIOTECanada’s Gold Leaf awards recognize both companies and individuals who have made significant contributions to the biotech industry in Canada. The remarkable individuals and companies recognized through the Gold Leaf Awards are great examples of the core strengths of Canada’s biotech ecosystem. Nominations are now being accepted (deadline August 5, 2022). The awards will be given out during BIONATION September 28-29, 2022...READ MORE

A new labour market intelligence study that will help provide a better understanding of the jobs and skills employers are looking for is underway for BC’s dynamic life sciences sector. The project is led by Life Sciences British Columbia with funding provided through the Canada-British Columbia Labour Market Development Agreement as part of the Sector Labour Market Partnerships program with the Ministry of Advanced Education and Skills Training...READ MORE

The In Vivo Lab Technician is a key member of Virogin’s Pharmacology and Toxicology team, ensuring the oncolytic virus product pipeline animal testing is conducted with the highest standard of care, ensuring accurate experimental results. The In Vivo Lab Technician’s responsibilities will be split 50/50 between wet-lab work and administrative/paperwork.

The Manager/Senior Manager, Trial Operations will work flexibly across a number of clinical stage trials and projects, acting as a study lead and manager for select clinical trials, and be hands-on in data compilation, review and analysis, clinical trial set-up and management, and operational support activities. This is an excellent opportunity for someone with strong organizational skills and the ability to work independently on a variety of tasks and projects. In addition, the successful candidate must have strong project management experience, excellent collaboration skills, demonstrate good judgement, be flexible and detail oriented.